Twist Bioscience Corporation splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Sep 30, 2025 was Ngs Tools at $208.1 million, 55% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Sep 30, 2025
|
FY 2024
Sep 30, 2024
|
FY 2023
Sep 30, 2023
|
FY 2022
Sep 30, 2022
|
FY 2021
Sep 30, 2021
|
FY 2020
Sep 30, 2020
|
FY 2019
Sep 30, 2019
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
432
|
377
|
313
|
245
|
204
|
132
|
90
|
54
|
| Ngs Tools |
—
|
208
+23.0%
share 55.3%
|
169
+36.7%
share 54.0%
|
124
+24.6%
share 50.5%
|
99
+36.7%
share 48.8%
|
73
+65.1%
share 54.9%
|
44
+109.2%
share 48.9%
|
21
share 38.7%
|
| Synthetic Genes |
—
|
114
+22.6%
share 30.2%
|
93
+26.0%
share 29.6%
|
74
+19.6%
share 30.0%
|
62
+57.9%
share 30.2%
|
39
+10.7%
share 29.4%
|
35
+31.7%
share 39.1%
|
27
share 49.1%
|
| Antibody Discovery |
—
|
23
+15.4%
share 6.2%
|
20
-12.3%
share 6.5%
|
23
-4.1%
share 9.5%
|
24
+246.0%
share 11.9%
|
7
share 5.3%
|
—
|
—
|
| Oligo Pools |
—
|
20
+19.7%
share 5.4%
|
17
+16.7%
share 5.4%
|
14
+16.6%
share 5.9%
|
12
+54.5%
share 6.1%
|
8
+76.9%
share 6.1%
|
5
-1.1%
share 5.0%
|
5
share 8.4%
|
| Dna And Biopharma Libraries |
—
|
11
-19.7%
share 3.0%
|
14
+36.6%
share 4.5%
|
10
+65.9%
share 4.2%
|
6
+8.3%
share 3.0%
|
6
-10.6%
share 4.3%
|
6
+211.8%
share 7.0%
|
2
share 3.7%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TWST (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1581280
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.